

# Cytokines, Kynurenine and the Chemistry of Sickness Behavior

ABSURD HEALTH INSTITUTE · 2026-10-16 · Established immune-neural signaling; transdiagnostic models incomplete

## Abstract

During infection or inflammation, people often withdraw socially, sleep differently, lose appetite, slow their movement and find less pleasure in daily life. These experiences resemble components of depression without being equivalent to major depressive disorder. Immune signaling through cytokine networks, tryptophan metabolism and central neural pathways offers one explanation for the overlap. The clinical challenge is determining when the pathway is primary, secondary or incidental.

## Sickness behavior is adaptive until it becomes costly

Transient sickness behavior can conserve energy and alter priorities during infection. Peripheral cytokine signaling affects the central nervous system through vascular, humoral and neural routes. Changes in sleep architecture, appetite, fatigue and motivation may arise without a primary psychiatric lesion. However, prolonged immune activation, repeated stress or chronic systemic illness could contribute to a persistent affective burden. Calling all such presentations “inflammatory depression” prematurely erases important differences in the underlying causes.

## Tryptophan is not one pathway

Immune activation can regulate indoleamine 2,3-dioxygenase and the kynurenine pathway, diverting tryptophan metabolism through compounds with complex immunological and neural effects. Some kynurenine metabolites interact with excitatory neurotransmission or oxidative pathways, while others may have different actions. A peripheral kynurenine measurement cannot be assumed to reveal synaptic concentrations or receptor effects. Diet, hepatic metabolism, kidney function and inflammatory status all complicate interpretation.

## What interventions teach us

Clinical experiments using inflammatory modulation have not produced a general cure for depression. A randomized infliximab trial found no overall efficacy in treatment-resistant depression, with exploratory suggestions that inflammatory status might matter for subgroup response. That pattern supports phenotype-specific questions and cautions against treating elevated CRP as a stand-alone prescription for immune suppression. It also illustrates how a mechanism can be biologically sound without yielding a broadly effective drug strategy.

## A discriminating model

A more useful classification would separate acute sickness behavior, depression with medical inflammatory comorbidity, hypothesized immune-modified depressive phenotypes and clear central inflammatory neurological disease. These categories differ in duration, symptom architecture, biomarkers and treatment implications. None justifies assuming that psychiatric suffering is always a sign of a hidden pathogen, nor that emotional experience has no biological consequences.

## Conclusion

Cytokine–kynurenine signaling creates a meaningful bridge between systemic illness and mental symptoms. Its predictive value depends on careful phenotyping and direct biological measurement rather than broad claims that depression is simply inflammation.

## Selected readings

- Raison et al., Randomized infliximab trial
- Dalmau et al., neuroimmune disease and psychiatric symptoms